The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of luveltamab tazevibulin vs investigator’s choice of chemotherapy in patients with recurrent platinum-resistant ovarian cancer (PROC) expressing folate receptor alpha (FRα): The REFRaME-01 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase 2/3 study.
 
Ana Oaknin
Consulting or Advisory Role - AGENUS; AstraZeneca; Clovis Oncology; Corcept Therapeutics; Daiichi Sankyo; Debiopharm Group; Deciphera; Eisai; Exelixis; Genmab; GlaxoSmithKline; Immunogen; ITeos Therapeutics; Merck Sharp & Dohme; Mersana; Myriad Genetics; Novocure; OneXerna Therapeutics, Inc.; PharmaMar; Regeneron; Roche; Seagen; Shattuck Labs; Sutro Biopharma; Zentalis
Research Funding - Abbvie (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Bristol-Myers Squibb International Corporation (BMS) (Inst); Clovis Oncology (Inst); Eisai (Inst); Immunogen (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); PharmaMar (Inst); Regeneron (Inst); Roche (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; PharmaMar; Roche
 
Jung-Yun Lee
Consulting or Advisory Role - AstraZeneca; MSD; Roche; Takeda
Research Funding - Ascendis Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Eisai (Inst); Immunogen (Inst); Janssen Oncology (Inst); Merck (Inst); Mersana (Inst); MSD (Inst); Novartis (Inst); OncoQuest Pharmaceuticals (Inst); Roche (Inst); Seagen (Inst); Synthon (Inst); Takeda (Inst)
 
David Cibula
Consulting or Advisory Role - Akeso Biopharma; AstraZeneca; GlaxoSmithKline; Mersana; MSD; Novocure; Roche; Sotio
 
Yeh Chen Lee
Speakers' Bureau - AstraZeneca
Research Funding - BeiGene (Inst)
 
Russell J. Schilder
Consulting or Advisory Role - Celsion; Eisai; Incyte
 
Annika Auranen
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; MSD Oncology
Travel, Accommodations, Expenses - GlaxoSmithKline
 
Bo Gao
Consulting or Advisory Role - BeiGene; IMPAC Medical Systems; IMPAC Medical Systems; MSD
 
David Shao Peng Tan
Stock and Other Ownership Interests - Asian Microbiome Library
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; Merck Serono; MSD; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Eisai; Genmab; MSD; Roche
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); BerGenBio (Inst); Byondis BV (Inst); Karyopharm Therapeutics (Inst); Roche (Inst); Zeria Pharmaceuticals Co Ltd (Inst)
(OPTIONAL) Uncompensated Relationships - Asia-Pacific Gynecologic Oncology Trials Group; Gynecologic Cancer Group Singapore; Gynecological Cancer InterGroup
 
Amit M. Oza
Consulting or Advisory Role - AstraZeneca; MorphoSys
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Merck (Inst)
(OPTIONAL) Uncompensated Relationships - Ozmosis Research
 
Rowan Miller
Consulting or Advisory Role - AZD; Clovis Oncology; Ellipses Pharma; GlaxoSmithKline; Merck KGaA; Roche
Speakers' Bureau - AZD; Clovis Oncology; GlaxoSmithKline; Roche
Travel, Accommodations, Expenses - AstraZeneca; Tesaro
 
Vanda Salutari
Honoraria - AstraZeneca; GlaxoSmithKline; MSD Oncology; Novocure; PharmaMar
Consulting or Advisory Role - AstraZeneca; Novocure
Travel, Accommodations, Expenses - GlaxoSmithKline; PharmaMar
 
Giulia Tasca
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; MSD Oncology
Speakers' Bureau - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Travel, Accommodations, Expenses - Pharmamar
 
David M. O'Malley
Consulting or Advisory Role - Adaptimmune; Agenus; AstraZeneca; Clovis Oncology; Corcept Therapeutics; DualityBio; Eisai; Elevar Therapeutics; GlaxoSmithKline; GOG Foundation; Immunogen; Imvax; Laekna Therapeutics; Merck; Mersana; Novartis; Novocure; Novocure; OncoC4; Onconova Therapeutics; Regeneron; Roche; Seagen; Sutro Biopharma; Umoja Biopharma; Verastem
Research Funding - Abbvie (Inst); Abbvie/Stemcentrx (Inst); Acerta Pharma (Inst); Advaxis (Inst); Ajinomoto (Inst); Ajinomoto (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BBI Healthcare (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Clovis Oncology (Inst); Deciphera (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Ergomed (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Immunogen (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); NovoCure (Inst); OncoQuest (Inst); Pfizer (Inst); PharmaMar (Inst); Precision Therapeutics (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); SeaGen (Inst); Seagen (Inst); Sumitomo Dainippon Pharma Oncology, Inc. (Inst); Sutro Biopharma (Inst); Tesaro (Inst); TRACON Pharma (Inst); Verastem (Inst)
 
Bradley J. Monk
Leadership - US Oncology
Honoraria - Acrivon Therapeutics; Adaptimmune; Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Serono/Merck; Genmab/Seattle Genetics; GOG Foundation; Gradalis; HenRui; ImmunoGen; Iovance Biotherapeutics; Karyopharm Therapeutics; Laekna Health Care; Merck; Mersana; Myriad Pharmaceuticals; Novartis; Novocure; OncoC4; Panavance Therapeutics; Pfizer; Pieris Pharmaceuticals; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GSK; US Oncology; Vascular Biogenics; Verastem; Zentalis
Consulting or Advisory Role - Adaptimmune; Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Serono/Merck; Genmab/Seattle Genetics; GOG Foundation; Gradalis; Gradalis; HenRui; ImmunoGen; Iovance Biotherapeutics; Karyopharm Therapeutics; Laekna Health Care; Merck; Mersana; Myriad Pharmaceuticals; Novartis; Novocure; OncoC4; Panavance Therapeutics; Pfizer; Pieris Pharmaceuticals; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GSK; US Oncology; Vascular Biogenics; Verastem; Zentalis
Speakers' Bureau - AstraZeneca; Clovis Oncology; Eisai; Merck; Roche/Genentech; TESARO/GSK
Research Funding - Advaxis (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Genentech (Inst); Immunogen (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Regeneron (Inst); Tesaro (Inst)
 
Bhavana Pothuri
Honoraria - Bio Ascend; OncLive; PER; Projects in Knowledge; YALE UNIVERSITY
Consulting or Advisory Role - AstraZeneca; Celsion; Curio Science; Eisai; GlaxoSmithKline; GOG Foundation; Immunogen; Imvax; Incyte; Incyte; InxMed; Lilly; Merck; Mersana; Onconova Therapeutics; Peerview; R-Pharm; Regeneron; Seagen; Signatera; Sutro Biopharma; WebMD
Research Funding - Acrivon Therapeutics (Inst); Agenus (Inst); AstraZeneca (Inst); Celgene (Inst); Celsion (Inst); Clovis Oncology (Inst); Eisai (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Incyte (Inst); InxMed (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Mersana (Inst); Novocure (Inst); NRG Oncology (Inst); Onconova Therapeutics (Inst); Seagen (Inst); Sutro Biopharma (Inst); Takeda (Inst); Tesaro (Inst); Toray Industries (Inst); VBL Therapeutics (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - GOG Foundation; Merck; Seagen
Other Relationship - Society of Gynecologic Oncology
 
Lin Lu
Employment - Sutro Biopharma
Stock and Other Ownership Interests - Sutro Biopharma
 
Craig Berman
Employment - Sutro Biopharma
Stock and Other Ownership Interests - Sutro Biopharma
 
Anne Borgman
Employment - Sutro Biopharma
Stock and Other Ownership Interests - Sutro Biopharma
 
R. Wendel Naumann
Consulting or Advisory Role - Agenus; AstraZeneca; Bristol-Myers Suibb; Eisai; EMD Serono; Genelux; GlaxoSmithKline/Tesaro; GOG Partners; Immunogen; Laekna Therapeutics; Merck Sharp & Dohme; Seagen; Sutro Biopharma
Speakers' Bureau - Seagen
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline/Tesaro (Inst); Gynecologic Oncology Group (Inst); Mersana (Inst); OncoMed (Inst); Sutro Biopharma (Inst)